.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,852,708

« Back to Dashboard

Details for Patent: 6,852,708

Title: Use of hyaluronic acid and forms to prevent the narrowing of the vascular walls
Abstract:For the prevention of the narrowing of the tubular walls of an animal after the tubular walls have been traumatized, the administration of a therapeutically effective non-toxic amount of a form of Hyaluronic Acid selected from Hyaluronic Acid, salts thereof and combinations thereof to the animal to prevent narrowing of the tubular walls.
Inventor(s): Falk; Rudolf Edgar (Toronto, CA), Ascuali; Samuel Simon (Toronto, CA), Turley; Eva Anne (Winnipeg, CA)
Assignee: Jagotec AG (Hergisweik, CH)
Filing Date:Dec 22, 1997
Application Number:08/996,470
Claims:1. A pharmaceutical composition comprising together with pharmaceutically acceptable diluents, adjuvants and/or carriers: (1) a form of hyaluronic acid selected from the group consisting of hyaluronic acid, pharmaceutically acceptable salts thereof and combinations thereof wherein the concentration of the form of hyaluronic acid is 2% by weight of the composition, and (2) an agent selected from the group consisting of a non-steroidal anti-inflammatory drug, a restenosis inhibiting drug, Vitamin C, a free radical scavenger, an anti-oxidant and combinations thereof for inhibiting the narrowing of the vascular walls of an animal after the vascular walls have been traumatized, the amount of the form of hyaluronic acid being an effective non-toxic amount incorporated into the composition together with a therapeutically effective amount of the agent to inhibit vascular wall narrowing, wherein the amount of the form of hyaluronic acid is an effective amount to inhibit the narrowing of the vascular walls of the animal and the agent enhances the effect of the form of hyaluronic acid in the inhibition of the narrowing of the vascular walls, and wherein the form of hyaluronic acid is in an amount of between 10 mg to 1000 mg having a molecular weight of greater than 150,000 daltons and less than 750,000 daltons.

2. A method of inhibiting or reducing the adherence of smooth muscle cells, leukocytes, and/or platelets, the method comprising administering a therapeutically effective non-toxic amount of sodium hyaluronate to a human in need thereof, wherein the molecular weight of the sodium hyaluronate is greater than 150,000 daltons and less than 750,000 daltons.

3. The method of claim 2 wherein adherence of leukocytes or platelets is inhibited or reduced.

4. A method of inhibiting the adherence of smooth muscle cells, endothelial cells, leukocytes, platelets, cholesterol, or macrophages to vascular walls, the method comprising administering a therapeutically effective non-toxic amount of a form of hyaluronic arid to a human in need thereof, wherein the form of hyaluronic acid is selected from the group consisting of hyaluronic acid, pharmaceutically acceptable salts thereof and combinations thereof and wherein the molecular weight of the form of hyaluronic acid is greater than 150,000 daltons and less than 750,000 daltons.

5. A method of reducing the adherence of smooth muscle cells, endothelial cells, leukocytes, platelets, cholesterol, or macrophages to vascular walls, the method comprising administering a therapeutically effective non-toxic amount of a form of hyaluronic acid to a human in need thereof, wherein the form of hyaluronic acid is selected from the group consisting of hyaluronic arid, pharmaceutically acceptable salts thereof and combinations thereof and wherein the molecular weight of the form of hyaluronic acid is greater than 150,000 daltons and less than 750,000 daltons.

6. The composition of claim 1 wherein the form of hyaluronic acid is sodium hyaluronate.

7. The composition of claim 1 wherein the composition is in injectable or intravenous form.

8. The composition of claim 1 wherein the amount of the form of hyaluronic acid is greater than 200 mg and the agent is a non-steroidal anti-inflammatory drug.

9. The method of claim 4 wherein adherence of leukocytes or platelets is inhibited.

10. The method of claim 4 wherein the form of hyaluronic acid is sodium hyaluronate.

11. The method of claim 4 wherein adherence of leukocytes or platelets is inhibited and wherein the form of hyaluronic acid is sodium hyaluronate.

12. The method of claim 5 wherein adherence of leukocytes or platelets is reduced.

13. The method of claim 5 wherein the form of hyaluronic acid is sodium hyaluronate.

14. The method of claim 5 wherein adherence of leukocytes or platelets is reduced and wherein the form of hyaluronic arid is sodium hyaluronate.

15. A method of inhibiting arterial restenosis comprising administering to a human a pharmaceutical composition comprising together with pharmaceutically acceptable diluents, adjuvants and/or carriers: (1) a form of hyaluronic acid consisting of sodium hyaluronate, and (2) an agent selected from the group consisting of a non-steroidal anti-inflammatory drug, a restenosis inhibiting drug, Vitamin C, a free radical scavenger, an anti-oxidant and combinations thereof such that arterial restenosis after balloon angioplasty in humans is inhibited.

16. A method of inhibiting or reducing the adherence of leukocytes, the method comprising administering a therapeutically effective non-toxic amount of a form of hyaluronic acid to a human in need thereof, wherein the form of hyaluronic acid is selected from the group consisting of hyaluronic acid, pharmaceutically acceptable salts thereof and combinations thereof, and wherein the molecular weight of the form of hyaluronic acid is greater than 150,000 daltons and less than 750,000 daltons.

17. A method of inhibiting or reducing the adherence of smooth muscle cells, the method comprising administering a therapeutically effective non-toxic amount of a form of hyaluronic acid to a human in need thereof, wherein the form of hyaluronic acid is selected from the group consisting of hyaluronic acid, pharmaceutically acceptable salts thereof and combinations thereof, and wherein the molecular weight of the form of hyaluronic acid is greater than 150,000 daltons and less than 750,000 daltons.

18. A pharmaceutical composition comprising together with pharmaceutically acceptable diluents, adjuvants and/or carriers: (1) sodium hyaluronate, and (2) an agent selected from the group consisting of a non-steroidal anti-inflammatory drug, a restenosis inhibiting drug, Vitamin C, a free radical scavenger, an anti-oxidant and combinations thereof for inhibiting the narrowing of the vascular walls of an animal after the vascular walls have been traumatized, the amount of the sodium hyaluronate being an effective non-toxic amount incorporated into the composition together with a therapeutically effective amount of the agent to inhibit vascular wall narrowing, wherein the amount of the sodium hyaluronate is an effective amount to inhibit the narrowing of the vascular walls of the animal and the agent enhances the effect of the sodium hyaluronate in the inhibition of the narrowing of the vascular walls, wherein sodium hyaluronate is in an amount of between 10 mg to 1000 mg and has a molecular weight of greater than 150,000 daltons and less than 750,000 daltons, and wherein the composition is in injectable or intravenous form.

19. A pharmaceutical composition comprising together with pharmaceutically acceptable diluents, adjuvants and/or carriers: (1) sodium hyaluronate in an amount greater than 200 mg, and (2) a non-steroidal anti-inflammatory drug, which is present in a therapeutically effective amount to inhibit vascular wall narrowing, for inhibiting the narrowing of the vascular walls of an animal after the vascular walls have been traumatized, wherein the amount of the non-steroidal anti-inflammatory drug enhances the effect of the form of hyaluronic acid in the inhibition of the narrowing of the vascular walls, and wherein the sodium hyaluronate has a molecular weight of greater than 150,000 daltons and less than 750,000 daltons.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc